ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
aTYR PHARMA INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.17−0.00 (-1.32%)
Close on Oct 19, 2026
- Market cap
- $16.84M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Operating margin
-40856.3%−40704.1 pts over 5 years
Net margin
-39009.5%−38854.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -19.1% | -73.7% | -55.1% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -65.1% | -61.4% | -107.8% | |
| Return on assets | -55.0% | -43.3% | -78.1% | |
| Current ratio | 8.77 | 6.06 | 5.30 | |
| Debt to equity | 0.15 | – | – | |
| Net debt to EBITDA | 0.51× | – | – | |
| Capex to revenue | – | 1.9% | 40.5% | |
| Diluted shares | 2M | 9M | 93M |
Where the cash went
Fiscal 2021 to 2025, five years combined
aTYR PHARMA generated $239.29M from operations and spent $6.19M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$239.29M
Used
$6.19M
Capital expenditure$6.19M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-39009.5%
×Asset turnover0.00×
×Equity multiplier1.38×
=Return on equity, FY2025-107.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -39009.5% | 0.00× | 1.38× | -107.8% |
| FY2024 | -27243.8% | 0.00× | 1.35× | -79.7% |
| FY2023 | -14274.5% | 0.00× | 1.34× | -62.2% |
| FY2022 | -436.5% | 0.10× | 1.17× | -50.2% |
| FY2020 | -155.2% | 0.28× | 1.42× | -61.4% |
| FY2019 | -3844.5% | 0.01× | 1.62× | -59.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$74.12M
- Cash generatingOperating cash flow above zero-$61.99M
- Return on assets improvedROA up on the prior year-53.1% → -76.5%
- Earnings backed by cashOperating cash flow above net income-$61.99M vs -$74.12M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.48 → 5.30
- No dilutionShare count did not rise74M → 93M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00